4. Akutt myelogen leukemi (AML)

Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., Wang, S. A., Bagg, A., ... Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200-1228.

Burchert, A., Bug, G., Fritz, L. V., Finke, J., Stelljes, M., Röllig, C., Wollmer, E., Wäsch, R., ... Metzelder, S. K. (2020). Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). Journal of Clinical Oncology, 38(26), 2993-3002.

Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007). A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109(6), 1114-1124.

Clark, A., Thomas, S., Hamblin, A., Talley, P., Kulasekararaj, A., Grinfeld, J., Speight, B., Snape, K., ... Snowden, J. A. (2023). Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). British Journal of Haematology, 201(1), 35-44.

Cloos, J., Valk, P. J. M., Thiede, C., Döhner, K., Roboz, G. J., Wood, B. L., Walter, R. B., Wang, S., ... Heuser, M. (2026). 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood, 147(11), 1147-1167.

DiNardo, C. D., Jen, W. Y., Takahashi, K., Kadia, T. M., Loghavi, S., Daver, N. G., Xiao, L., Reville, P. K., ... Kantarjian, H. M. (2025). Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia, 39(4), 854-863.

DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., ... Pratz, K. W. (2020). Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 383(7), 617-629.

Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., ... Löwenberg, B. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood, 144(21), 2169-2173.

Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., ... Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424-447.

Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., ... Löwenberg, B. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345-1377.

Duong, V. H., Bhatnagar, B., Zandberg, D. P., Vannorsdall, E. J., Tidwell, M. L., Chen, Q., & Baer, M. R. (2015). Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia and Lymphoma, 56(6), 1718-22.

Farhadfar, N., Dias, A., Wang, T., Fretham, C., Chhabra, S., Murthy, H. S., Broglie, L., D'Souza, A., ... Pasquini, M. (2021). Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and cellular therapy, 27(5), 410-422.

Fredly, H., Ersvær, E., Kittang, A. O., Tsykunova, G., Gjertsen, B. T., & Bruserud, O. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical epigenetics, 5(1), 13.

Fredly, H., Gjertsen, B. T., & Bruserud, O. (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical epigenetics, 5(1), 12.

Geissler, K., Koristek, Z., Del Castillo, T. B., Novák, J., Rodríguez-Macías, G., Metzelder, S. K., Illes, A., Mayer, J., ... Lübbert, M. (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. British Journal of Haematology, 205(5), 1734-1745.

Giles, F. J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., ... Kantarjian, H. (2007). The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology, 136(4), 624-627.

Gratwohl, A., Stern, M., Brand, R., Apperley, J., Baldomero, H., de Witte, T., Dini, G., Rocha, V., ... European Group for Blood Marrow Transplantation the European Leukemia Net (2009). Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer, 115(20), 4715-26.

Higué, J., Orvain, C., Dumas, P. Y., Peterlin, P., Hospital, M. A., Barrière, S., Couturier, A., Carre, M., ... Récher, C. (2025). Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study. Blood cancer journal, 15(1), 141.

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., ... Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703-1719.

Lachowiez, C. A., Ravikumar, V. I., Othman, J., O'Nions, J., Peters, D. T., McMahon, C., Swords, R., Cook, R., ... Pollyea, D. A. (2024). Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood, 144(26), 2788-2792.

Larsen, I. K., Aagnes, B., Breivik, S., Hestad, J. J., Jakobsen, E., Johannesen, T. B., ... Lambert, P. C. (2026). Cancer in Norway 2025 - Cancer incidence, mortality, survival and prevalence in Norway Oslo: Norwegian Institute of Public Health, Cancer Registry of Norway. Hentet fra https://www.fhi.no/publ/2026/cancer-in-norway-2025/

Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., Heuser, M., Calado, R. T., ... Döhner, H. (2022). Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 386(16), 1519-1531.

Orvain, C., Bertoli, S., Peterlin, P., Desbrosses, Y., Dumas, P. Y., Iat, A., Hospital, M. A., Carre, M., ... Recher, C. (2024). Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study. Leukemia, 38(9), 1949-1957.

Pagliuca, S., Schmid, C., Santoro, N., Simonetta, F., Battipaglia, G., Guillaume, T., Greco, R., Onida, F., ... Ruggeri, A. (2024). Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. The Lancet. Haematology, 11(6), e448-e458.

Palmieri, R., Othus, M., Halpern, A. B., Percival, M. M., Godwin, C. D., Becker, P. S., & Walter, R. B. (2020). Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. Journal of Clinical Oncology, 38(35), 4163-4174.

Penack, O., Marchetti, M., Aljurf, M., Arat, M., Bonifazi, F., Duarte, R. F., Giebel, S., Greinix, H., ... Peric, Z. (2024). Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet. Haematology, 11(2), e147-e159.

Pollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., ... DiNardo, C. D. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical cancer research, 28(24), 5272-5279.

Potter, N., Jovanovic, J., Ivey, A., Othman, J., Thomas, A., Gilkes, A., Runglall, M., Kanda, A., ... Dillon, R. (2025). Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet. Haematology, 12(5), e346-e356.

Sartor, C., Brunetti, L., Audisio, E., Cignetti, A., Zannoni, L., Cristiano, G., Nanni, J., Ciruolo, R., ... Curti, A. (2023). A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. British Journal of Haematology, 202(3), 599-607.

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., ... Ravandi, F. (2019). Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. The Lancet. Haematology, 6(1), e29-e37.

Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106(8), 2912-9.

Versluis, J., Labopin, M., Niederwieser, D., Socie, G., Schlenk, R. F., Milpied, N., Nagler, A., Blaise, D., ... Mohty, M. (2015). Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia, 29(1), 51-7.

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O'Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., ... Ley, T. J. (2016). TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 375(21), 2023-2036.

WHO Classification of Tumours Editorial Board (2022). Haematolymphoid tumours (WHO classification of tumours, 5. utg.; vol. 11). Lyon: International Agency for Research on Cancer. Epub ahead of print. Hentet fra https://tumourclassification.iarc.who.int/welcome/